MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals DPO Ratio 2011-2026 | CASI
Annual DPO Ratio CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 123 | 141 | 474 | - | - | - | 51.4 K | 36.9 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 51.4 K | 123 | 17.8 K |
Quarterly DPO Ratio CASI Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 82.7 | 151 | 145 | - | 158 | 172 | 174 | - | 183 | 133 | 125 | - | 176 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 183 | 82.7 | 150 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
4.39 K | - | 4.01 % | $ 150 M |  Canada |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Biogen
BIIB
|
65.4 | $ 177.27 | 0.62 % | $ 25.8 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
60.1 | $ 81.19 | -0.98 % | $ 1.57 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Amgen
AMGN
|
49.6 | $ 339.82 | -0.91 % | $ 182 B | USA |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aytu BioScience
AYTU
|
186 | $ 2.56 | -0.78 % | $ 16.1 M | USA |
 |
Catalyst Biosciences
CBIO
|
18.8 | $ 10.0 | -1.43 % | $ 658 M | USA |
 |
Cerus Corporation
CERS
|
242 | $ 2.3 | -1.08 % | $ 424 M | USA |
 |
Cellectis S.A.
CLLS
|
975 | $ 3.81 | -4.51 % | $ 116 M |  France |
 |
Brickell Biotech
BBI
|
105 | - | -5.38 % | $ 6.06 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Catalyst Pharmaceuticals
CPRX
|
83.2 | $ 24.53 | -0.2 % | $ 2.91 B | USA |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.68 | 3.75 % | $ 80.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
21.1 | $ 13.77 | -2.45 % | $ 4.25 B | USA |
 |
AIkido Pharma
AIKI
|
32.8 K | - | 1.93 % | $ 17.4 M | USA |